Palisade Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Palisade Bio (PALI) with a Buy rating and $7 price target The firm thinks investors are looking at PALI-2108 “through the lens of older-generation, systemic PDE4 inhibitor programs, rather than the differentiating features of Palisade’s drug.” The firm says the data and design suggest PALI-2108 may be better and safer in ulcerative colitis.